[The study of therapeutic efficacy of two forms of risperidone--rileptid and rispolept in patients with schizophrenia].
Generic drugs represent a big part of the Russian pharmaceutical market, a number of registered copies of the same drug manufactured by different pharmaceutical companies being estimated as several tens of drugs that does not mean their equally high quality and complete interchangeability. A choice of optimal price-to-quality ratio of a drug among a great number of analogues is possible only with taking into account a number of factors related to a manufacturer, a drug and a patient. The most important index of interchangeability of generic drugs is their therapeutic equivalence to the original one. A study aimed to compare the therapeutic equivalence of two preparations of risperidone--original rispolept and generic rileptid--has been carried out. The comparison of efficacy and tolerability of the therapy has not revealed differences both in any of the parameters and in any stages of the study. In conclusion, the full therapeutic equivalence of generic drug rileptid to original rispolept is revealed.
Akhapkin
R V
RV
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016568:Drugs, Generic; D005260:Female; D006801:Humans; D008297:Male; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013810:Therapeutic Equivalency
D014150:Antipsychotic Agents; D016568:Drugs, Generic; D018967:Risperidone